Johnson & Johnson will pay $5.5 billion to settle ovarian cancer claims. This landmark settlement covers nearly all remaining talc lawsuits against the company. The deal requires acceptance from ninety-five percent of claimants for finalization. Johnson & Johnson stated the claims were meritless and sought closure. The company has long denied its talc products caused cancer.